ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

USC Ophthalmologists Announce Launch of Permanent Retinal Implant Study

  [ 15 votes ]   [ Discuss This Article ] • May 1, 2002

LOS ANGELES, April 30, 2002-- Ophthalmologists at the Keck School of Medicine of the University of Southern California have implanted a permanent retinal prosthesis-also known as a microelectronic retinal implant-into their first patient, as part of an FDA-approved feasibility trial. Researchers hope the retinal prosthesis, intended to stand in for the damaged retinal cells in people suffering from such blinding diseases as retinitis pigmentosa and macular degeneration, will one day be able to restore some degree of vision to these patients.

The investigational device was originally conceived of by Mark Humayun, M.D., Ph.D., professor of ophthalmology at the Keck School, associate director of research at the Doheny Retina Institute and Eugene de Juan, Jr., M.D., professor of ophthalmology and chief executive officer of the Doheny Retina Institute. The device has been developed by Valencia, Calif.-based Second Sight, LLC.

Enrollment for the trial will be ongoing, and will be conducted by physicians at the USC Doheny Retina Institute.

The first participant in this trial was chosen in early February, after undergoing a battery of tests to determine, among other things, whether or not his eye was capable of responding to the sort of electrical stimulation given off by the implant.

The surgery took place on Feb. 19 at USC University Hospital's Outpatient Surgery Center and was performed by Humayun, who is also the principal investigator on this FDA-approved investigational trial.

The retinal prosthesis measures 4 millimeters by 5 millimeters, and is studded with 16 electrodes in a 4-by-4 array.

"Each electrode can excite a lot of nerve cells," says Humayun, "though we don't yet know exactly how many."

The device is Second Sight's first model to be permanently implanted in a patient. "This is a major milestone," says Robert Greenberg, M.D., Ph.D., president and CEO of Second Sight, LLC, the developers of the device. "This trial is just the first significant step towards our development of a commercial retinal prosthesis."

Although the device is constructed to be switched on permanently, in early tests it will only be turned on in the clinic, under medical supervision. "This patient and the other trial patients can keep the implant indefinitely," says Humayun, "and it may eventually be converted to continual use. But right now, when they walk out of the hospital, it will be turned off."

Once activated, visual signals from a video camera will be sent to the intraocular electrode array attached to the retina via the receiver that is implanted behind the patient's ear. The signal will then be recreated by stimulating the appropriate electrodes.

Although components of the retinal prosthesis have been tested in the past, it was always done on a temporary basis, with the prosthesis being removed less than an hour after being implanted. In this trial, the prosthesis is intended to be a permanent implant; unless complications occur, the working electronics will remain in place indefinitely. It is the first wireless implantable device of its kind.

Still, Humayun cautions, this is only the first step in a long journey. Testing the retinal prosthesis will take a good deal of time, he notes, because "it's a Class III device-the highest-risk device, according to the FDA. That's because it's an implant that will be left in for the rest of the person's life."

Other participants in the surgery included: de Juan; USC oculoplastic surgeon Michael Burnstine, M.D.; otolaryngologist Dennis Maceri, M.D., associate professor of clinical medicine; James Weiland, Ph.D., Keck School assistant professor of ophthalmology; Greenberg; and Gretchen Van Boemel, Ph.D., Keck School assistant professor of ophthalmology.

Funding to support the research and development of the retinal prosthesis implanted in this trial was provided by the National Institutes of Health/National Eye Institute and Second Sight, LLC. Other funding towards the development of a retinal prosthesis has been provided by the National Science Foundation, the Department of Energy, the Office of Naval Research, the Whitaker Foundation, The Foundation Fighting Blindness, the Defense Advanced Research Projects Agency and Second Sight, LLC.

De Juan, Humayun and their colleagues were recruited to the Doheny Eye Institute and the Keck School of Medicine in August of 2001 to establish the Doheny Retina Institute. USC University Hospital supported the recruitment of the team and is building state-of-the-art operating rooms to further their advancements in patient care.

Created with the vision to "relieve the suffering of our patients with retinal diseases, including age-related macular degeneration, a major cause of vision loss in the United States," the Doheny Retina Institute's goal is to bring "new hope, then relief and answers" to its patients.

Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Energy NADH™ 12.5mg FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Astaxanthin - A Little-Known but Power-Packed Nutrient Astaxanthin - A Little-Known but Power-Packed Nutrient
Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream
Safely Burn Away Body Fat Safely Burn Away Body Fat

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map